IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT
The development of an antitumor vaccine based on autologous dendritic cells (DCs) for bladder cancer treatment is extremely relevant today due to the proven high immunological potency of this type of tumor. Vaccination with DCs-based drugs as a monotherapy or in combination with other methods of tre...
| Main Authors: | , , |
|---|---|
| Format: | Article |
| Language: | Russian |
| Published: |
ABV-press
2018-07-01
|
| Series: | Успехи молекулярной онкологии |
| Subjects: | |
| Online Access: | https://umo.abvpress.ru/jour/article/view/143 |
| _version_ | 1826559182704214016 |
|---|---|
| author | A. S. Ilnitskaya A. B. Danilova I. A. Baldueva |
| author_facet | A. S. Ilnitskaya A. B. Danilova I. A. Baldueva |
| author_sort | A. S. Ilnitskaya |
| collection | DOAJ |
| description | The development of an antitumor vaccine based on autologous dendritic cells (DCs) for bladder cancer treatment is extremely relevant today due to the proven high immunological potency of this type of tumor. Vaccination with DCs-based drugs as a monotherapy or in combination with other methods of treatment has shown to be effective in cancer therapy. The vaccine administration is considered to be safe, the associated side effects are insignificant and can be characterized as undesirable phenomena of 1st or 2nd degree. There are a number of issues that arise while creating DCs vaccines that need to be carefully resolved. Among them, the problem of selecting potential targets for the vaccine treatment, the ways to enhance the potency of the vaccine, and the selection of technology for obtaining a sufficient number of functional DCs should be specifically mentioned. The review focuses on the use of autoantigen or alloantibody material for the activation of DCs, and the results of experimental and clinical studies of DCs vaccines in bladder cancer. |
| first_indexed | 2024-03-12T04:58:11Z |
| format | Article |
| id | doaj.art-ed9ae3eac6af41d3a31974930d0152ed |
| institution | Directory Open Access Journal |
| issn | 2313-805X 2413-3787 |
| language | Russian |
| last_indexed | 2025-03-14T08:56:19Z |
| publishDate | 2018-07-01 |
| publisher | ABV-press |
| record_format | Article |
| series | Успехи молекулярной онкологии |
| spelling | doaj.art-ed9ae3eac6af41d3a31974930d0152ed2025-03-02T12:45:05ZrusABV-pressУспехи молекулярной онкологии2313-805X2413-37872018-07-0152162310.17650/2313-805X-2018-5-2-16-23119IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENTA. S. Ilnitskaya0A. B. Danilova1I. A. Baldueva2Research Institute of Carcinogenesis, N. N. Blokhin National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaN.N. Petrov National Medical Research Center of Oncology, Ministry of Health of RussiaThe development of an antitumor vaccine based on autologous dendritic cells (DCs) for bladder cancer treatment is extremely relevant today due to the proven high immunological potency of this type of tumor. Vaccination with DCs-based drugs as a monotherapy or in combination with other methods of treatment has shown to be effective in cancer therapy. The vaccine administration is considered to be safe, the associated side effects are insignificant and can be characterized as undesirable phenomena of 1st or 2nd degree. There are a number of issues that arise while creating DCs vaccines that need to be carefully resolved. Among them, the problem of selecting potential targets for the vaccine treatment, the ways to enhance the potency of the vaccine, and the selection of technology for obtaining a sufficient number of functional DCs should be specifically mentioned. The review focuses on the use of autoantigen or alloantibody material for the activation of DCs, and the results of experimental and clinical studies of DCs vaccines in bladder cancer.https://umo.abvpress.ru/jour/article/view/143bladder cancerimmunotherapydendritic-cell vaccineclinical trials |
| spellingShingle | A. S. Ilnitskaya A. B. Danilova I. A. Baldueva IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT Успехи молекулярной онкологии bladder cancer immunotherapy dendritic-cell vaccine clinical trials |
| title | IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT |
| title_full | IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT |
| title_fullStr | IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT |
| title_full_unstemmed | IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT |
| title_short | IMMUNOTHERAPY BASED ON DENDRITIC CELLS IN BLADDER CANCER TREATMENT |
| title_sort | immunotherapy based on dendritic cells in bladder cancer treatment |
| topic | bladder cancer immunotherapy dendritic-cell vaccine clinical trials |
| url | https://umo.abvpress.ru/jour/article/view/143 |
| work_keys_str_mv | AT asilnitskaya immunotherapybasedondendriticcellsinbladdercancertreatment AT abdanilova immunotherapybasedondendriticcellsinbladdercancertreatment AT iabaldueva immunotherapybasedondendriticcellsinbladdercancertreatment |